title: Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution.
abstract: BACKGROUND
  The authors explored the prognostic factors and clinical outcomes of patients who had malignant peripheral nerve sheath tumors (MPNST) with and without neurofibromatosis type 1 (NF-1).
  
  
  METHODS
  Two hundred five patients with localized MPNST who underwent surgery at the Istituto Nazionale per lo Studio e la Cura dei Tumori (Milan, Italy) over 25 years were reviewed. Forty-six patients had concomitant NF-1 syndrome, and 159 patients did not. Local recurrence, distant metastases, and survival rates were studied.
  
  
  RESULTS
  One hundred thirty patients presented with primary disease, and 75 patients had locally recurrent tumors. The disease-specific mortality rate was 43% at 10 years, with a continuously disease-free survival rate of no greater than 40%. Presentation with either primary or recurrent disease, tumor size, and tumor site (trunk vs. extremity) were the strongest independent predictors of survival. Margin status and radiation therapy also played a role, mostly related to their effect on local outcome. Pathologic grade influenced distant metastases, but only a trend for survival could be observed. No significant independent differences between patients with and without NF-1 were observed.
  
  
  CONCLUSIONS
  To the authors' knowledge, this was among the largest single-institution series to date. The results confirmed that patients with MPNST share similar prognostic factors with patients who have other soft tissue sarcomas and have some of the worst clinical outcomes. The presence of NF-1 syndrome per se did not affect survival, but patients with NF-1 were more likely to have larger tumors. Therefore, such patients should be followed carefully to detect disease as early as possible.
authors.affiliation: Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
authors.forename: Matteo
authors.initials: M
authors.lastname: Anghileri
authors.forename: Rosalba
authors.initials: R
authors.lastname: Miceli
authors.forename: Marco
authors.initials: M
authors.lastname: Fiore
authors.forename: Luigi
authors.initials: L
authors.lastname: Mariani
authors.forename: Andrea
authors.initials: A
authors.lastname: Ferrari
authors.forename: Chiara
authors.initials: C
authors.lastname: Mussi
authors.forename: Laura
authors.initials: L
authors.lastname: Lozza
authors.forename: Paola
authors.initials: P
authors.lastname: Collini
authors.forename: Patrizia
authors.initials: P
authors.lastname: Olmi
authors.forename: Paolo G
authors.initials: PG
authors.lastname: Casali
authors.forename: Silvana
authors.initials: S
authors.lastname: Pilotti
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gronchi
mesh_terms: D000293:Adolescent; D000328:Adult; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D018317:Nerve Sheath Neoplasms / Q000150:complications / Q000401:mortality* / Q000601:surgery / Q000628:therapy; D009456:Neurofibromatosis 1 / Q000150:complications*; D011379:Prognosis; D015996:Survival Rate